Every Immune Tolerance Network (ITN) clinical trial integrates a set of genetic, cellular, and immunological studies that are designed to explore the underlying mechanisms of tolerance and disease. They help to identify new clinical phenotypes by stratifying individuals in the clinical trials, and discover new biomarkers that may illuminate drug targets or be useful for personalizing therapy. To accomplish this, the ITN has partnered with the following core laboratories and facilities that utilize state-of-the-art and custom-made assays.
Harlan Robins, Adaptive Biotechnologies, Seattle, WA
Adaptive Biotechnologies performs immune profiling of T cell and B cell receptors using ImmunoSEQ technology.
Ulrich Hoffmeuller, Epiontis, Berlin, Germany
Epigenetic analysis of immune cells is performed at Epiontis GmbH, a biotechnology company located in Berlin, Germany.
Steven Kleiboeker, ViracorIBT, Lees Summit, MO
ViracorIBT is a CLIA-certified, molecular and immunological diagnostics laboratory with approximately 16,000 sq. ft. of laboratory space located in Lee’s Summit, MO (within the Kansas City metropolitan area).
Michael Sheldon, Rutgers University, Piscataway, NJ
The Rutgers University Cell & DNA Repository serves as the Immune Tolerance Network's Central Cell Isolation Facility.
William Kwok, Benaroya Research Institute, Seattle, WA
MHC Class II tetramer reagents and staining procedures allow for the direct detection of antigen specific T cells by flow cytometry.
Anthony Demetris, University of Pittsburgh, Pittsburgh, PA
The Division of Transplantation Pathology at the University of Pittsburgh Medical Center offers a comprehensive consultation service in solid organ transplantation pathology to community and university based physicians.
Liping Yu, University of Colorado, Aurora, CO
The Immune Tolerance Network Autoantibody Core analyzes patient serum for the presence of autoantibodies using semi-automated, high-throughput radioassays.
Maura Rosetti, Donald Carter, Xinmin Li, UCLA, Los Angeles, CA
The primary goal of the HLA Typing Core is to provide sequence level typing using DNA collected from participants in ITN trials. UCLA also serves as the ITN Nucleic Acid Isolation Core, isolating and aliquoting DNA and/or RNA from ITN specimens across many ITN studies.